NCT00721656
Completed
Phase 2
A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes
Overview
- Phase
- Phase 2
- Intervention
- Placebo
- Conditions
- Dry Eye Syndromes
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Corneal-conjunctival staining
- Status
- Completed
- Last Updated
- 17 years ago
Overview
Brief Summary
To evaluate the efficacy and safety of KLS-0611 compared to placebo in patients with dry eye syndromes.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Corneal and conjunctival damage
- •Insufficiency of lacrimal secretion
- •Ocular symptom
Exclusion Criteria
- •Severe ophthalmic disorder
- •Punctual plugs or surgery for occlusion of the lacrimal puncta
Arms & Interventions
Placebo
Intervention: Placebo
KLS-0611
Intervention: KLS-0611
Outcomes
Primary Outcomes
Corneal-conjunctival staining
Time Frame: 4 weeks
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
A Phase II Study of KCT-0809 in Patients With Dry Eye SyndromeDry Eye SyndromesNCT01427816Kissei Pharmaceutical Co., Ltd.180
Completed
Phase 2
Safety and Efficacy of TOP1630 for Dry Eye SyndromeDry Eye SyndromeNCT03088605ORA, Inc.69
Completed
Phase 2
Study of TOP1630 for Dry Eye SyndromeDry Eye SyndromeNCT03833388Topivert Pharma Ltd202
Completed
Phase 2
[KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye SyndromeDry Eye SyndromesNCT05017844Kukje Pharma222
Completed
Phase 3
Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry EyeKeratoconjunctivitis SiccaNCT00037661Merck Sharp & Dohme LLC222